Wild-type mice and Pparα-null mice were pretreated orally with fenofibrate for 3 days, following which α-naphthylisothiocyanate (ANIT) was administered to induce cholestasis. The PPARα agonist WY14643 and JNK inhibitor SP600125 were used to determine the role of PPARα and the JNK pathway, respectively, in cholestatic liver injury. The same fenofibrate regimen was applied to investigate its beneficial effects on sclerosing cholangitis in a DDC-induced cholestatic model.
Introduction
Fenofibrate is an agonist for the nuclear hormone receptor PPARα. Clinically, fibrates are widely used for the treatment of hypertriglyceridaemia and mixed hyperlipidaemia associated with atherosclerosis (Fievet and Staels, 2009) . After activation by agonists, PPARα dimerizes with the retinoic X receptor and binds to the peroxisome proliferator response elements upstream of target genes involved in the metabolism and transport of lipids (Peters et al., 2005) . Fibrates are also effective for the treatment of metabolic diseases such as diabetes and hypertension, as well as protection against hepatotoxins such as acetaminophen (Day et al., 1993; Patterson et al., 2012; Song et al., 2016) .
Cholestasis, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), often results in the retention of bile salts (Hirschfield et al., 2010) . This occurs when the balance of production and transport of bile acids is disrupted, leading to liver fibrosis, cirrhosis and liver failure. In northern Europe, the incidence of PBC was estimated to be between 1 and 49 cases per million people year À1 , and the prevalence was between 7 and 402 per million people (Prince and James, 2003; Lazaridis and Talwalkar, 2007; Poupon, 2010) . In Asian countries, the prevalence of PBC was 400-500 cases per million (Sakauchi et al., 2005; Liu et al., 2010) . For PSC, the published incidence was as high as 1.3/100 000 year À1 and the prevalence was 16 per 100 000
people (Lindkvist et al., 2010; Molodecky et al., 2011; Boonstra et al., 2012; Hirschfield et al., 2013) . More than 50% of PSC patients need liver transplantation 10-15 years after the development of symptoms (Broome et al., 1996; Tischendorf et al., 2007; Claessen et al., 2009) . Ursodeoxycholic acid (UDCA) slows the progression of PBC in stages I and II. Despite the beneficial effects, UDCA remains ineffective in up to 50% of patients (Kaplan and Poupon, 2009; Carbone et al., 2013) . In 2016, obeticholic acid was approved by the FDA for the treatment of PBC. Thus, there is still a great need for additional therapeutic options for cholestatic disease. Besides its involvement in the metabolism of lipids, glucose and amino acids, PPARα has a role in bile acid homeostasis (Zhou et al., 2014) . In mice treated with the PPARα agonist WY14643 for 7 days, expression of the bile acid synthesis enzyme CYP8B1 (sterol 12α-hydroxylase) increases by fivefold, resulting in altered bile acid homeostasis (Hunt et al., 2000) . The PPARα activator gemfibrozil induces an upregulation of cholesterol 7α-hydroxylase (CYP7A1) and CYP8B1 and increases total bile acids (TBAs) in a dosedependent manner in wild-type mice but not in Pparα-null mice (Liu et al., 2014a) . In a colitis model, activation of a PPARα-UDP-glucuronosyltransferase signalling pathway accelerated the elimination of intestinal bile acids, resulting in suppression of farnesoid X receptor-FGF15 signalling. The subsequent up-regulation of hepatic CYP7A1 promoted the de novo synthesis of bile acid (Zhou et al., 2014) . In Pparα-null mice administered a cholic acid diet, an elevation of taurocholic acid and cholic acid was observed. In contrast, neither the latter metabolic disorder nor the effect on bile acid synthesis was noted in wild-type mice (Li et al., 2012) . These findings suggest that PPARα can have both a protective and a disruptive role in bile acid homeostasis.
Fibrate drugs are used to treat patients with chronic cholestatic liver disease refractory to UDCA monotherapy in the clinic. In 19 patients with early-stage PBC and an inadequate response to UDCA, treatment with UDCA plus bezafibrate for 3 months significantly improved serum biliary enzymes, IgM and cholesterol (Honda et al., 2013) . In 20 PBC patients who inadequately responded to UDCA, serum alkaline phosphatase (ALP) decreased from 214-779 to 60-384 U·L À1 when fenofibrate was administered in combination with UDCA for 48 weeks, (Levy et al., 2011) . In a retrospective cohort study, fenofibrate was associated with a significant improvement in ALP levels in PBC patients with an incomplete response to UDCA (Cheung et al., 2016) . In PBC patients treated with fenofibrate plus UDCA and bezafibrate plus UDCA, the serum ALP, γ-glutamyl transpeptidase and serum immunoglobulin M levels in the two groups were substantially improved compared with their baseline levels, indicating a therapeutic effect (Dohmen et al., 2013) . Although their therapeutic efficacy is evident, there is still no clinical guidelines directing fibrates for the treatment of cholestasis, and thus, physicians are reluctant to prescribe fenofibrate to cholestatic patients. In rat hepatocytes, ciprofibrate and WY14643 reduce Cyp7a1 and Cyp27a1 mRNA levels along with a reduction in enzymatic activities (Post et al., 2001) . In HepG2 cells, fenofibrate up-regulates the expression of human multidrug resistance protein 3 (MDR3, MDR2 in mouse; also known as ABCC2). And when incubated with rat isolated hepatocytes, fenofibrate increases the canalicular excretion of phosphatidylcholine (Ghonem et al., 2014) . Fibrates and WY14643 reduce p65 (NF-κB p65 subunit)-mediated activation of IL-1β by inducing the expression of the inhibitory factor IкBα in a PPARα-dependent manner (Delerive et al., 2000) . Thus, several mechanisms for the effects of fenofibrate against cholestasis that involve PPARα have been proposed, including the down-regulation of CYP7A1, up-regulation of MDR3 (ABCC2) and an anti-inflammatory action mediated by inhibiting NF-кB (Ghonem et al., 2015) . However, these studies were largely based on in vitro models and noncholestatic models.
In the present study, ANIT (α-naphthylisothiocyanate)-induced cholestasis and liver injury were evoked in a mouse model to evaluate the protective effect of fenofibrate. Wildtype and Pparα-null mice were used to determine the role of PPARα. Three doses of fenofibrate (5, 25 and 125 mg·kg À1 twice a day), the PPARα agonist WY14643 and JNK inhibitor SP600125 were used to explore the underlying mechanism. The data demonstrated that both PPARα and the dose used were critically important for the anti-cholestatic action of fenofibrate. JNK signalling was found to mediate the cholestatic liver injury and the protective effect of the PPARα agonist was mediated by inhibiting this signalling pathway.
the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Ethical approval was granted by the Animal Welfare and Ethics Review Board of the Medical School of Ningbo University, China. Animal studies were reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . The effect in a minimum of five mice per group was chosen as calculated by GPOWER.
ANIT-induced cholestasis and liver injury were evoked in a mouse model to evaluate the protective effect of fenofibrate. Wild-type and Pparα-null mice were used to determine the role of PPARα. Three doses of fenofibrate (5, 25 and 125 mg·kg À1 twice a day), the PPARα agonist WY14643
and JNK inhibitor SP600125 were used to explore its underlying mechanism. Prior to the experiments, male 8 to 10 week (24 to 28 g) wild-type and Pparα-null mice on the 129/Sv background were housed at the Medical School of Ningbo University Animal Services Unit (SPF) for 7 days at 23 ± 1°C, with a relative humidity of 60-70% and a light/dark cycle of 12 h with free access to water and standard mouse chow. The mice were kept in standard cages (n = 5) with aspen bedding. The wild-type mice were divided into eight groups (n = 5): vehicle/control (WT-C), ANIT/control (WT-A), ANIT/fenofibrate 5, 25 and 125 mg·kg À1 twice a day was administered to the indicated groups. Forty-eight hours after the administration of ANIT, the mice were weighed and killed by asphyxiation using carbon dioxide following blood collection. Liver tissues and gallbladder were harvested and weighed to determine changes in the liver and gallbladder. A section of freshly isolated liver tissue was excised and immediately fixed in 10% neutral buffered formalin after a brief wash with PBS. The remaining liver tissues were flash-frozen in liquid nitrogen and then stored at À80°C pending analysis.
To determine whether fenofibrate administration affects sclerosing cholangitis, we designed experiments to investigate the effects of this drug in a DDC-induced model of sclerosing cholangitis; the groups included wild-type vehicle/control (WT-C), DDC/control (WT-D) and DDC/fenofibrate 35 mg·kg À1 (WT-D-F25). Sclerosing cholangitis was induced by DDC challenge for 7 days (Pollheimer and Fickert, 2015) . Fenofibrate dissolved in corn oil was administered by oral gavage 3 days before DDC challenge. Twenty-four hours after the last dose of DDC and fenofibrate, the mice were killed and specimens were collected and analysed as above for protection phenotype.
Assessment of serum levels of fenofibric acid
An aliquot of 30 μL serum was spiked into 60 μL of acetonitrile with bezafibrate as internal standard. The mixtures were vortexed for 30 s and centrifuged at À20°C and 15 000× g for 20 min. The supernatant was analysed using a Shimadzu highperformance LC system (Kyoto, Japan) coupled with an API-4000 triple quadrupole mass spectrometer (Toronto, Canada).
Biochemical analysis
Total bilirubin (TBIL), ALP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), TBA and direct bilirubin (DBIL) in serum were assayed by the Spectra Max M5 (Molecular Devices, Sunnyvale, CA, USA). The analysis was carried out following the manufacturers' procedures described in the kits.
Histopathological assessment
Fixed liver tissues in the above experiments were dehydrated in a serial concentrations of alcohol and xylene followed by paraffin embedding. Four-micrometre serial sections were cut and stained with haematoxylin and eosin. Histopathological examination was performed using an Olympus BX51 light microscope. Ten sections per preparation were analysed blindly by a pathologist.
Quantitative PCR analysis
The total RNA from mouse hepatic tissues (20 mg) homogenized in Trizol reagent was determined by Multiskan Go (Thermo Scientific, Waltham, MA, USA). The reverse transcription system (20 μL) included the following items: 5 × Reaction buffer 4 μL, total RNA 1 μg, Oligo dT18 1 μL, Random primer 1 μL, 10 mM dNTPs Mix 2 μL, 200 U RevertAid M-MuLV RT 1 μL and 20 U Ribolock RNase inhibitor 1 μL. The cDNA synthesized was stored at À20°C and subjected to analysis within 7 days. The primer sequences, listed in Supporting Information Table S2 , were extracted from http://mouseprimerdepot.nci.nih.gov. Each 10 μL PCR system contained 1 μL total cDNA, LightCycle 480 SYBR Green I Master Mix (FastStart Taq DNA polymerase, reaction buffer, dNTP mix, SYBR Green I dye, and MgCl 2 ) 5 μL, forward primer 0.2 μL, reverse primer 0.2 μL, nuclease-free water 3.6 μL. Amplification was performed using reaction cycle at 95°C 10 s, 55°C 10 s and then 72°C 15 s. The fluorescence signal was detected at the end of each cycle. 18S rRNA was used as an internal control, and melting curve was used to confirm the specificity of the primers.
Western blot analysis
Liver tissues were homogenized by MagNA Lyser (Roche, Indianapolis, IN, USA) using RIPA buffer (1:10, g/v) containing 1% PMSF (Shanghai, China). Tissue debris was removed by centrifugation at 10 000× g and 4°C for 5 min. The total protein was quantified using a BCA protein assay kit (Beyotime Biotech Co. Ltd, Nantong, China). An equivalent volume of 5X SDS-PAGE sample loading buffer (Shanghai, China) was added to the tubes that were then boiled for 5 min. The samples were loaded and separated on 10% SDSpolyacrylamide gels.
The samples were transblotted onto PVDF membranes which were blocked with 5% fat-free milk at 37°C for at least 2 h. Membranes were incubated overnight with primary antibodies against p-MKK4 (phospho-mitogen-activated protein kinase kinase 4), t-MKK4 (total MMK4), p-JNK (phospho-JNK), t-JNK (total JNK), p-c-Jun (phospho-AP-1 transcription factor subunit), t-c-Jun (total c-Jun), t-p65, p-p65, p-STAT3 (phospho-STAT3), total STAT3 and GAPDH. After secondary antibody incubation for 1 h, the blotted membranes were exposed to ECL substrates (Advansta, Menlo Park, CA, USA) and the signals were detected by Tanon 4200SF (Tanon, Shanghai, China).
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data were presented as mean ± SD. The assignment of mice to different groups was randomized. The raw data were assessed independently by two co-authors to ensure the correctness of the conclusions. The investigators treating the mice were not aware of the pharmacological treatments of each group; each group was assigned a number during the assessment. Those who did the data analysis did not have access to the administration sheet. To detect a 25% change at a power 0.8 and α = 0.05 with 8% SD, the effect required a minimum of five mice per group as calculated using GPOWER. The statistical analysis was performed using the software SPSS Statistics, version 23 (IBM, Beijing, China). Differences among multiple groups were tested using one-way ANOVA followed by Dunnett's post hoc comparisons. Comparison between ANIT/DDC and CON, A-F25/D-F25/A-WY/A-SP and CON groups in two mice lines were tested by Student's t-test. A difference was considered significant when P < 0.05 and was marked with an asterisk in the graphs accordingly.
Materials
Fenofibrate was purchased from Shangqiu Chemry Chemicals Co. Ltd (Shangqiu, China). Fenofibric acid (FA), bezafibrate, ANIT, WY14643 and SP600125 were obtained from Sigma-Aldrich (St. Louis, MO, USA). TBA, ALP, ALT, AST, TBIL and DBIL assay kits were purchased from Yonghe Sunshine Technology (Changsha, China). Antibodies against p-MKK4 and t-MKK4, t-JNK and p-JNK, and p-c-Jun and t-c-Jun were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against p65 and the active form phospho-p65, total STAT3, p-STAT3 and GAPDH were acquired from Abcam (MA, USA). The reverse transcription kit and LightCycle 480 SYBR Green I Master Mix were obtained from Roche Diagnostics (Mannheim, Germany). All the other chemicals were of the highest grade available from commercial sources.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
Results

Pharmacokinetics of fenofibrate administration to mice
A calibration curve was constructed using authentic FA and the negative ion transition m/z 317.1/231 for FA was detected in multiple reactions monitoring mode (Supporting Information Figure S1A ). The plasma concentration of FA in groups WT-F5, WT-F25 and WT-F125 treated with fenofibrate were 0.16 ± 0.04, 1.24 ± 0.49 and 5.40 ± 0.95 μg·mL À1 respectively (Supporting Information Table S1 ). However, in the WT-A-F5, WT-A-F25 and WT-A-F125 groups, the FA concentrations were 0.83 ± 0.43, 0.96 ± 0.81 and 1.90 ± 1.29 μg·mL À1 respectively. Similar to the concentrations of the WT-F-25 group, the FA levels in the KO-A-F25 and KO-F-25 groups were 0.94 ± 0.47 and 0.88 ± 1.74 μg·mL À1 . The FA concentration in the WT-A-F5 group was higher than that in the WT-F5 group, and the concentration in the WT-A-F125 group was lower than that in the WT-F125 group (Supporting Information Figure S1B ). Based on a linear pharmacokinetic model, the dose of fenofibrate in humans producing the similar trough concentration as that in WT-A-F25 was estimated to be only 1/4-1/3 of the present dose for atherosclerosis (Supporting Information Table S1 ).
Fenofibrate protected against ANIT-induced cholestasis and liver injury
In the wild-type mice, serum ALP, TBA, TBIL, DBIL, ALT and AST were significantly increased in the ANIT group compared with the WT-C group (P < 0.05; Figure 1 ). In the WT-A-F25, but not WT-A-F5 or WT-A-F125 mice, the above indicators were totally inhibited compared with the WT-A group (P < 0.05). Wild-type mice treated with fenofibrate (WT-F5, WT-F25 and WT-F125) showed no hepatotoxicity. In the Pparα-null mouse groups, ALP, TBA, TBIL, DBIL ALT and AST were significantly increased in the KO-A group compared with the KO-C group (P < 0.05), which was similar to that in the WT-A group. However, the biochemical indicators in the KO-A-F25 group pretreated with fenofibrate at 25 mg·kg À1 twice a day were not inhibited compared with those in the KO-A group (Figure 1 ). Pathological analysis of the hepatic tissues in both the WT-C and KO-C groups exhibited normal histology ( Figure 2A ). The WT-A group exhibited a loss of cellular boundaries, degenerative changes and marked necrosis ( Figure 2B ). Similar destruction was observed in the WT-A-F5 and WT-A-F125 groups. In contrast, no pathological change was noted in the WT-F25 group ( Figure 2D ). In the Pparα-null mice, the liver injury was similar between the KO-A-F25 and KO-A groups ( Figure 2F , G). Thus, pretreatment with fenofibrate protected mice against the ANIT-induced liver injury, and this effect was dependent on both fenofibrate dose and PPARα activation.
Bile acid metabolism and transport were adaptively modified ANIT challenge decreased Cyp7a1 and Cyp8b1 mRNA levels in wild-type and Pparα-null mice compared with the control groups (P < 0.05). In the WT-A-F5, WT-A-F125, KO-A and KO-A-F25 groups, Cyp7a1 and Cyp8b1 mRNA levels were decreased similarly compared with WT/KO-C groups. However, in the WT-F25 group, Cyp7a1 and Cyp8b1 mRNA levels were significantly increased compared with the WT-A group (P < 0.05), similar to the WT-C (P > 0.05) group (Figure 3 A-C). In contrast, Mdr2 (Abcc2) mRNA was significantly increased in the WT-A group compared with the WT-C (P < 0.05), and these changes could be modified by fenofibrate in the A-F25 group. In the three wild-type groups treated with fenofibrate, Mdr2 mRNA was significantly increased in the WT-F5, WT-F25 and WT-F125 groups compared with the WT-C group (P < 0.05), and no modification of Cyp7a1 and Cyp8b1 mRNA was observed. Organic anion-transporting polypeptide 1 (OATP1 also known as OATP1C1) and multidrug resistance-related protein 4 (MRP4) are involved in the efflux of bile acids. Levels of Oatp1, Mrp3 and Mrp4 mRNA were modified by fenofibrate in a dose-dependent manner (P < 0.05). Oatp1 mRNA was significantly decreased in the two ANIT-treated groups in two mouse lines (P < 0.05), as well as the cholestatic groups WT-A-F5, WT-A-F125, KO-A and KO-A-F25. But Oatp1 mRNA level were also decreased in the WT-A-F25 group compared with the WT-C or WT-A group (P < 0.05; Figure 3D ). Mrp3 and Mrp4 mRNA was increased in ANIT-treated mice, and the WT-A-F5, WT-A-F125, KO-A and KO-A-F25 cholestatic groups when compared with the WT/KO-C group (P < 0.05). In the WT-A-F25 group, Mrp3 mRNA level was unchanged compared with the WT-C group, but Mrp4 mRNA was significantly increased (P < 0.05). Changes in expression of Oatp1 and Mrp4 mRNAs in the WT-A-F25 non-cholestatic group probably occurred because they were regulated by both bile acid feedback and fenofibrate action ( Figure 3D-F) .
BSEP (bile salt export pump also known as ABCB11) and OSTB (heteromeric organic solute transporter-β) are also involved in efflux bile acids. Neither of them was modified by fenofibrate, but both of their mRNAs were significantly increased in the two ANIT-treated groups and the WT-A-F5, WT-A-F125, KO-A and KO-A-F25 cholestatic groups (P < 0.05). Both mRNAs were unchanged in the WT-A-F25 non-cholestatic group. In comparison with moderate changes in levels of Bsep mRNA (2.8-5.2-fold), Ostb mRNA was sharply increased, suggesting different sensitivity to bile acid feedback and the potential contribution to bile acid detoxification (Supporting Information Figure S2A-D) . 
NF-кB, STAT3 and JNK pathways were differently activated
In wild-type mice, Il-1β mRNA was significantly increased in the cholestatic WT-A, WT-A-F5 and WT-A-F125 groups compared with the WT-C group (P < 0.05; Figure 4A ). In KO-A, KO-A-F25 and KO-F25 groups, it was significantly increased compared with KO-C group (P < 0.05; Figure 4B ). Increased Il-6 mRNA was not observed in the wild-type groups except for a moderate increase in the WT-A-F5 group. Il-6 mRNA was significantly increased in the KO-A, KO-A-F25 and KO-F25 groups compared with the KO-C group (P < 0.05; Figure 4C, D) . The Il-10 encoding the protective cytokine Fenofibrate acts against cholestatic liver injury BJP IL-10 was significantly increased in the WT-A group among all the wild-type groups (P < 0.05). Il-10 mRNA was significantly increased in the KO-A, KO-A-F25 and KO-F25 groups compared with the KO-C group (P < 0.05; Figure 4E , F). Tnf-α was not modified in the wild-type groups, but it was increased by only threefold to fivefold in the KO-A and KO-A-F25 groups compared with the KO-C group. These data indicated that increased inflammation occurred in the cholestatic groups, but it was unclear which of the above factors triggered the inflammation.
A dose-dependent inhibition of p-p65 was clearly observed in all groups treated with fenofibrate ( Figure 4G ). However, its inhibition was not observed in the Pparα-null groups. Activation of p-STAT3 was observed in both wildtype and Pparα-null mice, but was more pronounced in the latter group ( Figure 4G ). The STAT3 target gene mRNAs suppressor of cytokine signalling 3 (Socs3), fibrinogen α chain, fibrinogen β chain and fibrinogen γ chain were upregulated less than fourfold in the wild-type groups. In the KO-A and KO-A-F25 cholestatic groups, their expression was increased by 14-and 15-fold, 15-and 16-fold, 12-and 12-fold and 26-and 16-fold respectively (P < 0.05; Supporting Information Figure S3) . Thus, the fenofibrateinhibited NF-кB-STAT3 signalling was dependent on PPARα. However, the inhibition neither correlated with nor contributed to inhibition of cholestasis or hepatic injury in the two mouse lines.
Compared with the WT-C group, the c-Jun and c-Fos mRNAs were significantly increased in the WT-A, WT-A-F5, WT-A-F125 and WT-F125 groups (P < 0.05), but not in the WT-A-F25 group compared with the WT-C group ( Figure 5A, C) . In Pparα-null mice, the c-Jun and c-Fos mRNAs were significantly increased in the KO-A and KO-A-F25 groups (P < 0.05; Figure 5B, D) . The Western blot analysis showed that p-MKK4 was activated in the WT-A and WT-A-F5 groups but was inhibited in the WT-A-F25 and WT-A-F125 groups ( Figure 5E ). p-JNK was activated in the WT-A and WT-A-F5 groups, totally inhibited in the WT-A-F25 group, but only partly inhibited in WT-A-F125 group. In the Pparα-null mice, activation of p-MKK4 was not evident, but p-JNK was increased more in the three experimental groups than in the KO-C group ( Figure 5E ). Activation p-c-Jun was observed in all the cholestatic groups of the two mouse lines but was not in the WT-A-F25 and KO-F25 groups in which cholestasis was totally inhibited or did not occur ( Figure 5E ). Thus, the JNK pathway might contribute to cholestasis or hepatic injury in the two mouse lines.
WY14643 inhibited cholestatic liver injury and this was associated with JNK inhibition
In wild-type mice, serum TBA, ALT, TBIL and DBIL levels were significantly increased respectively in the WT-A group (P < 0.05). In WT-A-WY mice, the above indicators were totally inhibited (Figure 6A-D) . The WT-A group exhibited Effects of fenofibrate on the expression of inflammatory and anti-inflammatory factors associated with NF-κB and STAT3 signalling. (A, B) Il-1β mRNA levels in the wild-type and Pparɑ-null mice. (C, D) Il-6 mRNA levels in the wild-type and Pparɑ-null mice. (E, F) Il-10 mRNA levels in the wild-type and Pparɑ-null mice respectively. The mRNA levels were measured by Q-PCR and normalized by 18S rRNA. mRNA levels in the vehicle-treated control mice were set as 1 and the results expressed as mean ± SD (n = 5, * P < 0.05, compared with WT-C/KO-C; P < 0.05, compared with WT-A/KO-A). (G) Western blot analysis of NF-κB and STAT3 signalling mediated by PPARα. Data were from liver samples collected 5 days after fenofibrate treatment, and 2/5 of the liver tissues were randomly selected for Western blot analysis. GAPDH was used as a loading control.
JNK inhibitor SP600125 blocked ANIT-induced cholestatic liver injury
In comparison with the WT-A group, the ALP, TBA, TBIL and DBIL levels in WT-A-SP were not modified, suggesting that cholestasis occurred even after treatment with SP600125. However, the ALT and AST level in the WT-A-SP group was significantly decreased, indicating that cholestatic liver injury was inhibited ( Figure 7A-F) . Pathological analysis revealed no obvious alterations in liver histology in the WT-A-SP and WT-SP groups ( Figure 7G ), which confirmed a definite protective effect of SP600125. The JNK pathway was inhibited in the WT-SP-A group compared with the WT-A group as indicated by the level of p-JNK and p-c-Jun ( Figure 7H ). This effect was similar to that observed in the WT-A-F25 and the WT-A-WY group. These data indicate that the JNK pathway mediates the cholestatic liver injury, and its inhibition results in the attenuation of cholestatic liver injury by PPARα agonists.
Figure 5
Inhibition of the JNK pathway is involved in fenofibrate and PPARα-mediated protection. (A, B) c-Jun mRNA level in wild-type and Pparɑ-null mice. (C, D) c-Fos mRNA level in wild-type and Pparɑ-null mice respectively. (E) Western blots of components of the JNK signalling pathway in liver extracts. The mRNA levels were measured by Q-PCR and normalized by 18S rRNA. mRNA levels in the vehicle-treated control mice were set as 1 and the results expressed as mean ± SD. For Western blot analysis, the data were from liver samples collected 5 days after fenofibrate treatment, and two were randomly selected for protein analysis. (n = 5, * P < 0.05, compared with WT-C/KO-C;^P < 0.05, compared with WT-A/KO-A).
SP600125 inhibited cholestatic liver injury in the WT-A-F125 group
In comparison with the WT-A and WT-A-F125 group, the ALP, TBA, TBIL and DBIL levels in the WT-A-F-SP group were not modified, suggesting cholestasis occurred even though the mice had been treated with SP600125. However, the ALT and AST levels in the WT-A-F-SP group were significantly decreased, indicating that cholestatic liver injury was inhibited ( Figure 8A-F) . Pathological analysis revealed no alterations in liver histology in the WT-A-F-SP group ( Figure 8G ), which confirmed the protective effect of SP600125 and fenofibrate. The JNK pathway was inhibited in the WT-A-F-SP group compared with the WT-A and WT-A-F125 group as indicated by the level of p-JNK ( Figure 8H ). This was similar to that of the WT-A-F25 group and the WT-A-WY group. These data corroborated the involvement of JNK signalling in cholestatic liver injury and confirmed that incompletely inhibited JNK signalling mediated the hepatic injury in the WT-A-F125 group.
Fenofibrate protected against DDC-induced sclerosing cholangitis
In comparison with the WT-C group, the ALP, TBA, ALT, AST, TBIL and DBIL levels in the WT-D group were significantly increased. However, the ALP, TBA, ALT, AST, TBIL and DBIL levels in the WT-D-F25 group were not modified, indicating that cholestatic liver injury was inhibited by fenofibrate ( Figure 9A-F) . DDC feeding leads to ductular proliferation and cholangitis with onion skin type-like periductal fibrosis in WT-D group mice. No obvious alteration of the liver histology was observed in the WT-D-F25 group (Figure 9G ), which confirmed a definite protective effect of fenofibrate. This result suggests that fenofibrate is also an effective treatment for sclerosing cholangitis.
Discussion
Clinically, fenofibrate is prescribed at doses of 150-300 mg·day À1 for dyslipidaemia (Shirinsky et al., 2013; Harmer et al., 2015; Masana et al., 2015) . In monotherapy or in combination with UDCA, the fenofibrate dose for cholestatic liver diseases is usually between 100 and 200 mg·day À1 (Nakamuta et al., 2005; Walker et al., 2009; Levy et al., 2011) . According to the transition method based on body surface area, the equivalent dose in mice is 22.5-45 mg·kg À1 . In a mouse nonalcoholic steatohepatitis model, fenofibrate at 50 mg·kg À1 ·day À1 improved obesity, dyslipidaemia, liver dysfunction and NASH pathology (Honda et al., 2017) . In rodent models, fenofibrate at 100 and 200 mg·kg À1 ·day À1 partially improved ALP, γ-glutamyl transferase, TBA, ALT, AST, TNF-α and IL-1β levels (Cindoruk et al., 2007; El-Sisi et al., 2013) . Two preliminary experiments conducted in this study found the critical dose range was 5-125 mg·kg À1 twice daily.
In the present study, fenofibrate at 25 mg·kg À1 twice a day totally inhibited cholestasis but at 0.2-or 5-fold of the above dose it was ineffective, indicating that protection was dependent on fenofibrate dose. In human hepatocytes, the fenofibrate effect on MDR3 was dose-dependent between 12.5 and 50 μM. However, the effect was reduced when the concentration was increased to 125 μM (Ghonem et al., 2014) . It is reasonable to suggest that drugs at high doses may trigger some unknown factors that cause liver toxicity. Fenofibrate 125 mg·kg À1 twice a day was associated with incomplete inhibition of the JNK pathway. However, SP600125 was found to inhibit the hepatic injury in the WT-A-F125 group, suggesting that the lower efficacy of fenofibrate at 125 mg·kg À1 was due to incomplete inhibition of JNK signalling. At the steady state of fenofibrate in the clinic, the C ss max of FA is 9.0-9.6 μg·mL À1 under different regimens and the C ss min is 3.2-5.85 μg·mL À1 (Table 1) (Martin et al., 2003; Bergman et al., 2004) . In the present study, the C ss min of FA showed evidence of dose-dependence. The C ss min in the protected group treated with fenofibrate 25 mg·kg À1 twice a day was 1.24 ± 0.49 μg·mL À1 , which was only 1/5 to 2/5 of the FA C ss min level in humans. If this exposure level was also the most effective for humans, the calculated dose in humans could be between 42 ± 9.1 and 62 ± 9.4 mg·day À1 based on linear pharmacokinetics (Supporting Information Table S1 ). This dose range of fenofibrate was much lower than the specified doses for dyslipidaemia in the clinic. Thus, the dose-exposure-response relationship found in this study raises an interesting question: is it necessary and is it worth performing clinical trials to determine whether a lower fenofibrate dose produces better anti-cholestatic effects? Bile acid homeostasis depends on the balance among synthesis, uptake and basolateral and canalicular export of bile acids. In this study, mRNAs encoded by genes involved in increasing bile acid level in hepatocytes, Cyp7a1, Cyp8b1 and Oatp1, were all down-regulated in the cholestatic groups, while Cyp7a1and Cyp8b1 mRNAs were unchanged in the WT-A-F25-protected group. In contrast, Oatp1 mRNA was also down-regulated in the WT-A-F25 group because it was also affected by fenofibrate. This effect was in accord with that previously reported for MDR2, MRP3, MRP4, BSEP and OSTB, which are responsible for decreasing bile acid levels in hepatocytes (Kok et al., 2003) . Their mRNA expression patterns showed a tendency to be increased in all cholestatic groups, but were unchanged in the WT-A-F25 group. An exception was Mrp4 mRNA that was also increased in the WT-A-F25 group, because it was also affected by fenofibrate. This effect is in agreement with the increases in Mrp4 mRNA and protein expression induced by clofibrate observed previously (Delerive et al., 2000) . Considering the above common reactions, the effects of fenofibrate on the synthesis, uptake and export of bile acids are likely to be mainly adaptive responses, in agreement with an earlier perspective (Pogson et al., 1999; Yang et al., 2012) . Only the pharmacological regulation of Oatp1 and Mrp4 mRNA seemed to contribute to the detoxification effects of fenofibrate. This contrasts with a previous suggested mechanism that CYP7A1 and MDR3 are involved in the anti-cholestatic effect of fenofibrate (Ghonem et al., 2015) .
NF-κB activation leads to an increase in inflammatory factors including TNF-α, IL-1 and IL-6. And TNF-α in turn can activate NF-κB signalling (Sarma et al., 2014) . NF-кB is involved in hepatotoxicity and protection against hepatotoxins can be mediated by inhibiting NF-кB signalling (Liu et al., 2014b; Tan et al., 2016) . The PPARα agonists FA, ciprofibrate and WY14643 inhibit p65-mediated activation of Il-1β by inducing the inhibitory IкBα in human aortic cells (Delerive et al., 2000) . In human endothelial cells, fenofibrate and WY14643 reduced the promoter activity of vascular cell adhesion molecule 1 (VCAM1) by inhibiting the NF-κB pathway (Marx et al., 1999) . Thus, NF-кB was thought to be involved in the anti-cholestatic effects of fibrates (Ghonem et al., 2015) . In this study, NF-кB signalling in wild-type mice was inhibited in a dose-dependent manner and was unchanged in Pparɑ-null mice. These responses were in agreement with the reported role of PPARα in regulating NF-кB signalling. However, the effects of fenofibrate on cholestasis, which involve PPARα and are anti-inflammatory, were not mediated via inhibition of NF-кB. These observations do not support the classic view that NF-кB is involved in the inhibitory effects of fibrates on cholestatic liver injury (Ghonem et al., 2015) .
With regard to the STAT3 pathway, the p-STAT3 was slightly elevated in the WT-A group. In the wild-type groups pretreated with fenofibrate, the STAT3 pathway was inhibited in a dose-dependent manner. In Pparα-null mice, both the expression and phosphorylation of STAT3 were up-regulated in the KO-A and KO-A-F25 groups in which cholestasis and liver injury were evident. In agreement with these different effects on STAT3 signalling, the STAT3 target genes and the inflammatory factors were upregulated more in Pparɑ-null mice than those in wild-type mice. The difference in STAT3 signalling between the two mouse lines was probably associated with upstream NF-кB signalling, which was inhibited by PPARα only in wild-type mice. More importantly, these differences indicated the different levels of effector molecules between the two mouse lines with cholestasis, even though their toxic phenotype was similar. Thus, these data suggest that NF-кB and STAT3 signalling contribute little to the protective action of fenofibrate.
JNK activation is usually mediated by inflammatory cytokines, including TNF-α, IL-1 and TGF-β (Weston and Davis, 2007) . The synthesis and excretion of TNF-.alpha; and IL-1β is induced by bile acids in hepatic Kupffer cells (Miyake et al., 2000) . Cytokines, cholic acid and deoxycholic acid can in turn activate the JNK/c-Jun pathway (Li et al., 2002; Higuchi et al., 2004) . In cellular models, the JNK pathway is associated with bile acid metabolism regulation (Gupta et al., 2001; Li et al., 2002; Li et al., 2006) . However, the JNK pathway has not been shown to have a critical role in in vivo cholestatic models. In this study, JNK signalling was activated in all the cholestatic groups of the two mouse lines, as indicated by increased levels of p-MKK4, p-JNK and c-Jun. This activation profile correlated well with cholestasis and liver injury, which was repeated in the WY14643 experiment. In the SP600125 experiment, the hepatic injury was substantially attenuated when JNK signalling was partially inhibited. Thus, the cholestatic associated liver injury was blocked by inhibition of the JNK pathway. Also SP600125 (WT-A-F-SP group) reversed the liver toxicity observed in the WT-A-F125 group. This result confirmed the involvement of JNK signalling in cholestatic liver injury and supports the conclusion in this study. Combining the above data in three individual experiments, the protection against the ANIT-induced intrahepatic cholestasis mediated by fenofibrate is thought to occur via inhibition of the JNK pathway. This protection is dependent on fenofibrate dose, as well as the presence of PPARɑ.
The protective effect of fenofibrate in cholestasis provides a basis for the prevention of cholestatic liver disease. The curative effects of fenofibrate in cholestasis were not investigated due to the strong self-healing of the positive model. Fibrate drugs are used clinically in combination with UDCA to treat cholestatic patients (Levy et al., 2011) . The effect of combination therapy with UDCA remains to be investigated. The ANIT-induced model of cholestasis was mainly used in this study, because it is a widely accepted cholestasis model and the pathological changes are very similar to those of human intrahepatic cholestatic liver disease (Goldfarb et al., 1962; Fang et al., 2016; Liu et al., 2017) . DDC was used as an animal model to study chronic PSC (Liedtke et al., 2013) . In this DDC model, fenofibrate also acted against cholestasis and liver injury, suggesting its effectiveness as a treatment for sclerosing cholangitis (Figure 9 ). However, it remains to be investigated whether this effect also involves JNK activation. Based on the above data, a model describing the findings in the present study is shown in Figure 10 .
Taken together, the present results suggest that fenofibrate can effectively suppress cholestatic liver injury induced by ANIT and this protective effect occurred via inhibition of the JNK pathway. The dose-response relationship and dependence on PPARɑ of this effect of fenofibrate provide an important basis for clinical investigations of cholestasis treatment using fenofibrate. This widening of the pharmacological mechanisms of fenofibrate's protection against intrahepatic cholestasis offers further therapeutic opportunities for cholestatic liver diseases.
Figure 10
Proposed mode for the protection against intrahepatic cholestasis induced by fenofibrate. The protection involves inhibition of the JNK pathway and is dependent on both PPARα and the dose of the PPARα agonist. Solid lines denote biological responses, toxicological or pharmacological actions. Broken lines denote the responses or actions that contribute little to the indicated pathways or endpoints. Bold arrow of JNK pathway inhibition denotes that it is critically involved in the protective effects of fenofibrate. 
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